Myeloma Canada, an international affiliated partner of the IMF, is participating in a Canadian government funding review process for the treatment of myeloma with pomalidomide (Pomalyst®) and needs our help.
The drug is not yet available in Canada, however we anticipate that it will be approved soon, by Health Canada. Once approved, the drug will undergo a review to determine if its cost will be covered under public drug plans.
To participate in this review process, Myeloma Canada needs to gather information from myeloma patients and caregivers who have experience with pomalidomide. This is very important information that is needed for the approval process.
Therefore, if you or someone you care for has used pomalidomide (Pomalyst®) we kindly ask that you take 20 minutes to complete this survey. The close date and time for the survey is 5:00 p.m. on Friday, December 20th, 2013.
The link to the survey - https://www.surveymonkey.com/s/MCPatientCaregiverSurveyNov2013
Your voice will make a difference and show support for the funding for this treatment. Thousands of Canadians will benefit from it. Indeed, Myeloma Canada’s previous submissions have contributed to recent positive funding decisions for other myeloma treatments.
If you have any questions about this survey, please feel free to write to us at email@example.com.
Thank you for your participation; you are helping to make a difference!